Tannaz Moin1, Julie A Schmittdiel2, James H Flory3, Jessica Yeh4, Andrew J Karter2, Lydia E Kruge5, Dean Schillinger6, Carol M Mangione7, William H Herman8, Elizabeth A Walker5. 1. VA Greater Los Angeles Healthcare System, Los Angeles, California; David Geffen School of Medicine, University of California, Los Angeles, California; VA Health Services Research and Development, Center for Healthcare Innovation, Implementation and Policy, VA Greater Los Angeles, Los Angeles, California. Electronic address: tmoin@mednet.ucla.edu. 2. Kaiser Permanente Northern California Division of Research, Oakland, California. 3. Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York. 4. Department of Medicine, Johns Hopkins University, Baltimore, Maryland. 5. Albert Einstein College of Medicine, Bronx, New York. 6. Division of General Internal Medicine, University of California San Francisco, San Francisco, California. 7. David Geffen School of Medicine, University of California, Los Angeles, California. 8. Department of Medicine, University of Michigan, Ann Arbor, Michigan.
Abstract
CONTEXT: Prediabetes is prevalent and significantly increases lifetime risk of progression to type 2 diabetes. This review summarizes the evidence surrounding metformin use for type 2 diabetes prevention. EVIDENCE ACQUISITION: Articles published between 1998 and 2017 examining metformin use for the primary indication of diabetes prevention available on MEDLINE. EVIDENCE SYNTHESIS: Forty articles met inclusion criteria and were summarized into four general categories: (1) RCTs of metformin use for diabetes prevention (n=7 and n=2 follow-up analyses); (2) observational analyses examining metformin use in heterogeneous subgroups of patients with prediabetes (n=9 from the Diabetes Prevention Program, n=1 from the biguanides and the prevention of the risk of obesity [BIGPRO] trial); (3) observational analyses examining cost effectiveness of metformin use for diabetes prevention (n=11 from the Diabetes Prevention Program, n=1 from the Indian Diabetes Prevention Program); and (4) real-world assessments of metformin eligibility or use for diabetes prevention (n=9). Metformin was associated with reduced relative risk of incident diabetes, with the strongest evidence for use in those at highest risk (i.e., aged <60 years, BMI ≥35, and women with histories of gestational diabetes). Metformin was also deemed cost effective in 11 economic analyses. Recent studies highlighted low rates of metformin use for diabetes prevention in real-world settings. CONCLUSIONS: Two decades of evidence support metformin use for diabetes prevention among higher-risk patients. However, metformin is not widely used in real-world practice, and enhancing the translation of this evidence to real-world practice has important implications for patients, providers, and payers. Published by Elsevier Inc.
CONTEXT: Prediabetes is prevalent and significantly increases lifetime risk of progression to type 2 diabetes. This review summarizes the evidence surrounding metformin use for type 2 diabetes prevention. EVIDENCE ACQUISITION: Articles published between 1998 and 2017 examining metformin use for the primary indication of diabetes prevention available on MEDLINE. EVIDENCE SYNTHESIS: Forty articles met inclusion criteria and were summarized into four general categories: (1) RCTs of metformin use for diabetes prevention (n=7 and n=2 follow-up analyses); (2) observational analyses examining metformin use in heterogeneous subgroups of patients with prediabetes (n=9 from the Diabetes Prevention Program, n=1 from the biguanides and the prevention of the risk of obesity [BIGPRO] trial); (3) observational analyses examining cost effectiveness of metformin use for diabetes prevention (n=11 from the Diabetes Prevention Program, n=1 from the Indian Diabetes Prevention Program); and (4) real-world assessments of metformin eligibility or use for diabetes prevention (n=9). Metformin was associated with reduced relative risk of incident diabetes, with the strongest evidence for use in those at highest risk (i.e., aged <60 years, BMI ≥35, and women with histories of gestational diabetes). Metformin was also deemed cost effective in 11 economic analyses. Recent studies highlighted low rates of metformin use for diabetes prevention in real-world settings. CONCLUSIONS: Two decades of evidence support metformin use for diabetes prevention among higher-risk patients. However, metformin is not widely used in real-world practice, and enhancing the translation of this evidence to real-world practice has important implications for patients, providers, and payers. Published by Elsevier Inc.
Authors: William H Herman; Sharon L Edelstein; Robert E Ratner; Maria G Montez; Ronald T Ackermann; Trevor J Orchard; Mary A Foulkes; Ping Zhang; Christopher D Saudek; Morton B Brown Journal: Am J Manag Care Date: 2013 Impact factor: 2.229
Authors: William T Cefalu; John B Buse; Jaakko Tuomilehto; G Alexander Fleming; Ele Ferrannini; Hertzel C Gerstein; Peter H Bennett; Ambady Ramachandran; Itamar Raz; Julio Rosenstock; Steven E Kahn Journal: Diabetes Care Date: 2016-06-09 Impact factor: 19.112
Authors: Elizabeth K Ely; Stephanie M Gruss; Elizabeth T Luman; Edward W Gregg; Mohammed K Ali; Kunthea Nhim; Deborah B Rolka; Ann L Albright Journal: Diabetes Care Date: 2017-05-12 Impact factor: 19.112
Authors: Julie A Schmittdiel; Sara R Adams; Jodi Segal; Marie R Griffin; Christianne L Roumie; Kris Ohnsorg; Richard W Grant; Patrick J O'Connor Journal: Diabetes Care Date: 2013-11-22 Impact factor: 19.112
Authors: Luis A Rodríguez; Simón Barquera; Carlos A Aguilar-Salinas; Jaime Sepúlveda-Amor; Luz María Sánchez-Romero; Edgar Denova-Gutiérrez; Nydia Balderas; Lizbeth Moreno-Loaeza; Margaret A Handley; Sanjay Basu; Oliva López-Arellano; Alberto Gallardo-Hernández; Dean Schillinger Journal: Contemp Clin Trials Date: 2020-06-21 Impact factor: 2.226
Authors: Tannaz Moin; O Kenrik Duru; Norman Turk; Janet S Chon; Dominick L Frosch; Jacqueline M Martin; Kia Skrine Jeffers; Yelba Castellon-Lopez; Chi-Hong Tseng; Keith Norris; Carol M Mangione Journal: J Gen Intern Med Date: 2019-08-30 Impact factor: 6.473
Authors: Edward C Deehan; Eloisa Colin-Ramirez; Lucila Triador; Karen L Madsen; Carla M Prado; Catherine J Field; Geoff D C Ball; Qiming Tan; Camila Orsso; Irina Dinu; Mohammadreza Pakseresht; Daniela Rubin; Arya M Sharma; Hein Tun; Jens Walter; Christopher B Newgard; Michael Freemark; Eytan Wine; Andrea M Haqq Journal: Trials Date: 2021-02-17 Impact factor: 2.279